Cost-benefit analysis of universal tandem mass spectrometry for newborn screening

Pediatrics

Volumn 110, Issue 4, 2002, Pages 781-786

  Schoen, Edgar J ^a   Baker, John C ^a   Colby, Christopher J ^b   To, Trinh T ^a  

^a KAISER PERMANENTE MEDICAL CENTER   (United States)

^b DIVISION OF RESEARCH   (United States)

Author keywords

Costs and cost analysis; Homocystinuria; Inborn errors; Maple syrup urine disease; Mass; Metabolism; Neonatal screening; Spectrum analysis

Indexed keywords

ARTICLE; BREAST CANCER; CANCER SCREENING; COST BENEFIT ANALYSIS; COST CONTROL; HEALTH MAINTENANCE ORGANIZATION; HOMOCYSTINURIA; HUMAN; INBORN ERROR OF METABOLISM; MAJOR CLINICAL STUDY; MAPLE SYRUP URINE DISEASE; NEWBORN; NEWBORN SCREENING; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; TANDEM MASS SPECTROMETRY;

ADULT; BREAST NEOPLASMS; CALIFORNIA; COST SAVINGS; COST-BENEFIT ANALYSIS; FEMALE; HEALTH MAINTENANCE ORGANIZATIONS; HUMANS; INFANT, NEWBORN; LIFE EXPECTANCY; MALE; MASS SCREENING; MASS SPECTROMETRY; METABOLISM, INBORN ERRORS; NEONATAL SCREENING; PROSTATIC NEOPLASMS; QUALITY-ADJUSTED LIFE YEARS;

EID: 0036791226     PISSN: 00314005     EISSN: None     Source Type: Journal    
DOI: 10.1542/peds.110.4.781     Document Type: Article

References (44)

1. Naylor EW, Chace DH. Automated tandem mass spectrometry for mass newborn screening for disorders in fatty acid, organic acid, and amino acid metabolism. J Child Neurol. 1999;14(suppl 1):S4-S8
2. Simonsen H, Jensen UG. Technical aspects of neonatal screening using tandem mass spectrometry. Report from the 4th meeting of the International Society for Neonatal Screening. Acta Paediatr Suppl. 1999;432: 52-54
3. Ciske JB, Hoffman G, Hanson K, et al. Newborn screening in Wisconsin: program overview and test addition. WMJ. 2000;99:38-42
4. Muenzer J, Frazier DM, McCandless SE, et al. Incidence and follow-up evaluation of metabolic disorders detected by newborn screening in North Carolina using tandem mass spectrometry. MMWR Morb Mortal Wkly Rep. 2001;50(RR03):23-34. Synopses of selected papers presented at the Tandem Mass Spectrometry for Metabolic Disease Screening Among Newborns Workshop, San Antonio, Texas, June 2000. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5003a2.htm. Accessed May 30, 2002
5. Zytkovicz TH, Johnson D, Rojas D, et al. Testing newborn specimens by tandem mass spectrometry: the first 16 months' experience in the New England Program. MMWR Morb Mortal Wkly Rep. 2001;50(RR03):23-34. Synopses of selected papers presented at the Tandem Mass Spectrometry for Metabolic Disease Screening Among Newborns Workshop, San Antonio, Texas, June 2000. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5003a2.htm. Accessed May 30, 2002
6. Wiley V, Carpenter K, Wilcken B. Newborn screening with tandem mass spectrometry: 12 months' experience in NSW Australia. Acta Paediatr Suppl. 1999;88:48-51
7. Wilcken B, Wiley V. Tandem Mass Spectrometry in the New South Wales Newborn Screening Program. MMWR Morb Mortal Wkly Rep. 2001;50(RR03):23-34. Synopses of selected papers presented at the Tandem Mass Spectrometry for Metabolic Disease Screening Among Newborns Workshop, San Antonio, Texas, June 2000. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5003a2.htm. Accessed May 30, 2002
8. Wilcken B, Hammond J, Silink M. Morbidity and mortality in medium chain acyl coenzyme A dehydrogenase deficiency. Arch Dis Child. 1994; 70:410-412
9. Wilson CJ, Champion MP, Collins JE, et al. Outcome of medium chain acyl-CoA dehydrogenase deficiency after diagnosis. Arch Dis Child. 1999;80:459-462
10. Iafolla AK, Thompson RJ Jr, Roe CR. Medium-chain acyl-coenzyme A dehydrogenase deficiency: clinical course in 120 affected children. J Pediatr. 1994;124:409-415
11. Hannon WH, Grosse SD. Using tandem mass spectrometry for metabolic disease screening among newborns. MMWR Morb Moral Wkly Rep. 2001;50(RR03):1-22. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5003al.htm. Accessed May 30, 2002
12. Chace DH, DiPema JC, Naylor EW. Laboratory integration and utilization of tandem mass spectrometry in neonatal screening: a model for clinical mass spectrometry in the next millennium. Acta Paediatr Suppl. 1999;88:45-47
13. Charrow J, Goodman SI, McCabe ERG, et al. ACMG/ASHG statement. Tandem mass spectrometry in newborn screening. Genet Med. 2000;2: 267-269
14. Pollitt RJ, Green A, McCabe CJ, et al. Neonatal screening for inborn errors of metabolism: cost, yield and outcome. Health Technol Assess. 1997;1:1-202
15. Cederbaum S, Vilain E. Newborn screening for inborn errors of metabolism is going to expand: are we ready? J Pediatr. 1999;134:666-667
16. Andersson HC, Marble M, Shapira E. Long-term outcome in treated combined methylmalonic acidemia and homocystinemia. Genet Med. 1999;1:146-150
17. Sniderman LC, Lambert M, Giguère R, et al. Outcome of individuals with low-moderate methylmalonic aciduria detected through a neonatal screening program. J Pediatr. 1999;134:675-680
18. Pollitt RJ. Tandem mass spectrometry screening: proving effectiveness. Acta Paediatr Suppl. 1999;88:40-44
19. Kwon C, Farrell PM. The magnitude and challenge of false-positive newborn screening test results. Arch Pediatr Adolesc Med. 2000;154: 714-718
20. Green A, Pollitt RJ. Population newborn screening for inherited metabolic disease: current UK perspectives. J Inherit Metab Dis. 1999;22: 572-579
21. Starrett DA. Foundations of Public Economics. New York, NY: Cambridge University Press; 1988:191-193
22. Lipscomb J, Weinstein MC, Torrance GW. Time preference. In: Gold ME, Siegel JE, Russell LB, et al, eds. Cost-Effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996:216-234
23. Johnston SC, Gress DR, Kahn JG. Which unruptured cerebral aneurysms should be treated? A cost-utility analysis. Stroke. 1999;30:1984
24. Kallmes DF, Kallmes MH. Cost-effectiveness of angiography performed during surgery for ruptured intracranial aneurysms. AJNR Ant J Neuroradiol. 1997;18:1453-1462
25. King JT Jr, Sperling MR, Justice AC, et al. A cost-effectiveness analysis of anterior temporal lobectomy for intractable temporal lobe epilepsy. J Neurosurg. 1997;87:20-28
26. Langfitt JT. Cost-effectiveness of anterotemporal lobectomy in medically intractable complex partial epilepsy. Epilepsia. 1997;38:154-163
27. Pollitt RJ, Leonard JV. Prospective surveillance study of medium chain acyl-CoA dehydrogenase deficiency in the UK. Arch Dis Child. 1998;79: 116-119
28. Thompson IM, Optenberg SA. An overview cost-utility analysis of prostate cancer screening. Oncology. 1995;9:141-145
29. Vijan S, Hofer TP, Hayward RA. Cost-utility analysis of screening intervals for diabetic retinopathy in patients with type 2 diabetes mellitus. JAMA. 2000;283:889-896
30. Younossi ZM, Singer ME, McHutchison JG, et al. Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C. Hepatology. 1999;30:1318-1324
31. Groeneveld PW, Kwong JL, Liu Y, et al. Cost-effectiveness of automated external defibrillators on airlines. JAMA. 2001;286:1482-1489
32. Morton DH, Strauss KA, Robinson DL, et al. Diagnosis and treatment of maple syrup disease: a study of 36 patients. Pediatrics. 2002;109: 999-1008
33. Baric I, Zschocke J, Christensen E, et al. Diagnosis and management of glutaric aciduria type I. J Inherit Metab Dis. 1998;21:326-340
34. Morton DH. Through my window-remarks at the 125th year celebration of Children's Hospital of Boston. Pediatrics. 1994;94:785-791
35. Yoshino M, Aoki K, Akeda H, et al. Management of acute metabolic decompensation in maple syrup urine disease: a multi-center study. Pediatr Int. 1999;41:132-137
36. Tada K, Tateda H, Arashima S, et al. Follow-up study of a nation-wide neonatal metabolic screening program in Japan. A collaborative study group of neonatal screening for inborn errors of metabolism in Japan. Eur J Pediatr. 1984;142:204-207
37. Bodegard G, Fyro K, Larsson A. Psychological reactions in 102 families with a newborn who has a falsely positive screening test for congenital hypothyroidism. Acta Paediatr Scand Suppl. 1983;304:1-21
38. Cayler GG, Lynn DB, Stein EM. Effect of cardiac "nondisease" on intellectual and perceptual motor development. Br Heart J. 1973;35: 543-547
39. Bergman AB. The menace of mass screening. Am J Public Health. 1977; 67:601-602
40. Clayton EW. Issues in state newborn screening programs. Pediatrics. 1992;90:641-646
41. Fyro K, Bodegard G. Four-year follow-up of psychological reactions to false positive screening tests for congenital hypothyroidism. Acta Paediatr Scand. 1987;76:107-114
42. Hall S, Bobrow M, Marteau TM. Psychological consequences for patents of false negative results on prenatal screening for Down's syndrome: retrospective interview study. BMJ. 2000;320:407-412
43. Matorn D. Tandem mass spectrometry in newborn screening. Endocrinologist. 2002;12:50-57
44. California Insurance Code. Section 10123.89. Available at: http://www.leginfo.ca.gov/calaw.html. Accessed November 29, 2001